The UK NHS position is unambiguous: vaping is not risk-free but is substantially less harmful than smoking. The 2015 Public Health England (now OHID) report concluded vape is approximately 95% safer than smoking, a figure subsequently endorsed by the Royal College of Physicians 2024 evidence review. King’s College London 2022 review concluded “vaping poses a small fraction of the risks of smoking” with “significantly lower exposure to harmful substances.” UK Chief Medical Officer Dame Sue Atkinson summary: “if you smoke, vaping is much safer, but if you do not smoke, do not vape.”

Documented short-term vape harms per UK NHS, peer-reviewed research and clinical observation: throat and airway irritation (PG-related, common), increased airway resistance (small effect, mostly resolves on cessation), cough especially in new vapers (transient for most), nicotine cardiovascular effects (heart rate +10-15 bpm, BP +7-10 mmHg per session), dry mouth and dehydration, nicotine dependence and withdrawal on cessation, EVALI (e-cigarette/vape-associated lung injury, primarily from illegal THC products containing vitamin E acetate, very rare in UK regulated nicotine vape). Pneumonia, bronchitis and other lung infections show slightly elevated rates in vapers per US research, though smaller than in smokers.

Unknown long-term effects: vape is too new for definitive long-term harm data. Cigarette smoking harm became clear after 20-30 years of population exposure; vape has been mass-market only since around 2010. Cancer research UK and Royal College of Physicians: there is no good evidence vape causes cancer, but cancer-causing substances present in tobacco smoke have also been detected at lower levels in vape vapour, raising the possibility long-term use may increase risk of some smoking-related diseases. Levels are substantially lower than in tobacco cigarettes. UK House of Commons Library 2026 review: “uncertainty about long-term health risks has likely underpinned the NHS recommendation that vaping should only be used by adults as a smoking cessation tool.” For UK adults: vape is a clear win for current smokers; an unknown net cost for never-smokers.

Why “95% safer than smoking” is the UK consensus figure

The PHE/OHID ~95% safer figure originated in a 2015 expert review and has been challenged and re-examined multiple times. It remains the UK consensus because: First, removal of combustion: smoking burns tobacco at ~900°C, producing thousands of chemical compounds via pyrolysis. Vape heats e-liquid at ~150-250°C, producing far fewer chemical compounds. Tar (the carcinogenic black residue from combustion) is absent. Carbon monoxide (a major cardiovascular toxin in smoking) is absent. Polycyclic aromatic hydrocarbons (Group 1 carcinogens) are absent or vastly reduced. Second, biomarker studies: vapers who completely switched from smoking show dramatically reduced levels of tobacco-specific nitrosamines (carcinogens) and volatile organic compounds. King’s College 2022 review: “significantly lower levels in vapers.” Third, modelling: even worst-case estimates of vape harm (including all unknown long-term effects) place risk at small fraction of smoking. Fourth, observed cessation outcomes: ASH 2024 data shows nearly 3 million UK smokers have successfully quit using vape over past 5 years; cardiovascular biomarkers improve after switching. Limitations of the 95% figure: it is an estimate based on incomplete long-term data; the true figure could be higher or lower; specific products and use patterns vary. But the direction of effect (vape much safer than smoking) is well-established across UK, US and European reviews. UK government, NHS and Royal College of Physicians all endorse vape for smoking cessation on this basis.

What we actually know about short-term vape harms

Six categories of documented short-term harm. First, airway irritation: PG (propylene glycol) is hygroscopic and dries airway surfaces; many vapers experience throat irritation, cough, dry mouth especially when starting. Usually transient. Resolves on switching to higher-VG liquid. Second, increased airway resistance: small studies show vape increases airway resistance acutely, though forced expiratory volume (FEV1) and forced vital capacity (FVC) are mostly preserved. Effects mostly reverse on cessation. Third, nicotine cardiovascular effects: well-documented heart rate (+10-15 bpm) and blood pressure (+7-10 mmHg systolic) per session. For UK adults with existing heart disease, may matter clinically. Fourth, EVALI: serious lung injury syndrome, peaked in 2019-2020 US outbreak, primarily from illegal THC products with vitamin E acetate. UK regulated nicotine vape products do not contain vitamin E acetate. UK risk is very low but non-zero. Fifth, respiratory infections: US research shows slightly elevated rates of pneumonia, bronchitis, other infections in vapers. Mechanism unclear (possibly immune effects of inhaled propylene glycol, glycerin or flavourings). Sixth, nicotine dependence: clinical condition with withdrawal on cessation. All these short-term harms are documented; all are substantially smaller than smoking harms. For current smokers, the trade-off heavily favours vape; for never-smokers, the risk-benefit favours not starting.

What UK regulation does to limit vape harm

UK has one of the world’s most robust vape regulatory frameworks. Tobacco and Related Products Regulations 2016 (TRPR) implements the EU Tobacco Products Directive: maximum 20mg/ml nicotine concentration, maximum 2ml tank/pod size, ingredient disclosure to MHRA, banned ingredients list (including vitamin E acetate, diacetyl, certain colourings, dangerous chemicals). MHRA (Medicines and Healthcare products Regulatory Agency) operates the notification system: all UK vape products must be notified to MHRA before sale, with safety data and ingredient lists reviewed. June 2025: single-use disposable vapes banned (environmental + youth concern). October 2026: new Vaping Products Duty (tax on e-liquid). 2027: anyone born from 1 January 2009 will never legally be sold tobacco. UK retail standards: GDP-licensed retailers (Trading Standards), age verification (18+), packaging restrictions, no advertising/sponsorship. Our Omagh and Strabane stores follow all UK TRPR requirements: products notified to MHRA, age verification at point of sale, no sales to under-18s, retail records maintained. Counterfeit and illegal vape products bypass these regulations and may contain banned ingredients, higher than legal nicotine concentrations, or unknown contaminants. UK vapers should purchase only from UK-licensed retailers. The regulatory framework substantially limits vape harm; illegal market undermines this.

For UK adults wanting to understand vape risk vs benefit, the four NHS positions below cover almost all situations.

For UK adults wondering whether vape is bad for them personally, the answer depends on context. For current smokers: vape is a clear public health win, substantially reducing harm. For never-smokers: vape adds small but non-zero risk for no benefit. For under-18s: vape sale is illegal and use causes documented harm. UK regulatory framework (TRPR, MHRA, retail standards) substantially limits vape harm when products are purchased from licensed UK retailers. Our Omagh and Strabane teams stock TPD-compliant products from registered UK suppliers and can advise on harm reduction pathways for current smokers.